Information Provided By:
Fly News Breaks for June 7, 2017
JAZZ
Jun 7, 2017 | 06:16 EDT
Following the Phase III data for Jazz Pharmaceuticals' dopamine-norepinephrine reuptake inhibitor JZP-110 in patients with excessive daytime sleepiness associated with obstructive sleep apnea and narcolepsy, Piper Jaffray analyst David Amsellem says JZP-110 is "clearly differentiated from that of mainstay treatments Provigil and Nuvigil." The analyst views the stock's valuation as attractive and reiterates an Overweight rating on the shares with a $182 price target.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.